Article thumbnail

Characterization of bortezomib-adapted I-45 mesothelioma cells

By Lidong Zhang, James E Littlejohn, Yu Cui, Xiaobo Cao, Chander Peddaboina and W Roy Smythe
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2000). AJ: MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain.
  2. (2008). Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol Cancer Ther
  3. (2007). Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res
  4. (2006). Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Differ
  5. (2009). Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia
  6. (2008). G: Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood
  7. (2008). Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
  8. (2003). KC: A phase 2 study of bortezomib in relapsed, refractory myeloma.
  9. (2007). KC: Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood
  10. (2002). KC: NFkappa B as a therapeutic target in multiple myeloma.
  11. (2001). KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res
  12. (2008). Kuhn DJ: Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res
  13. (2006). LH: Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood
  14. (2002). Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line. Gene Ther
  15. (2008). Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat
  16. (2001). MG: c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells.
  17. (2005). Nickoloff BJ: Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res
  18. (2008). Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line. Exp Hematol
  19. (1998). Ploegh HL: A proteolytic system that compensates for loss of proteasome function.
  20. (2006). Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol Ther
  21. (2004). Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol
  22. (2008). RA: An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma. Clin Lymphoma Myeloma
  23. (2006). Success in translational research: lessons from the development of bortezomib. Nat Rev Drug Discov
  24. (2004). The development of proteasome inhibitors as anticancer drugs. Cancer Cell
  25. (2003). The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res
  26. (2004). The proteasome: a suitable antineoplastic target. Nat Rev Cancer